ES2194279T3 - Composiciones de ciclodextrina que contienen un derivado de avermectina o de milbemicina. - Google Patents

Composiciones de ciclodextrina que contienen un derivado de avermectina o de milbemicina.

Info

Publication number
ES2194279T3
ES2194279T3 ES98310562T ES98310562T ES2194279T3 ES 2194279 T3 ES2194279 T3 ES 2194279T3 ES 98310562 T ES98310562 T ES 98310562T ES 98310562 T ES98310562 T ES 98310562T ES 2194279 T3 ES2194279 T3 ES 2194279T3
Authority
ES
Spain
Prior art keywords
milbemicine
avermectine
cyclodextrine
derivative
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98310562T
Other languages
English (en)
Inventor
David Ringshaw
Ninh On
Philip Edward Moss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2194279T3 publication Critical patent/ES2194279T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

ESTA INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE AL MENOS UN COMPUESTO ANTHELMINTICAMENTE ACTIVO QUE SEA UNA AVERMECTINA O MILBEMICINA, EN FORMA DE UN COMPLEJO CON AL MENOS UNA CICLODEXTRINA.
ES98310562T 1998-01-20 1998-12-22 Composiciones de ciclodextrina que contienen un derivado de avermectina o de milbemicina. Expired - Lifetime ES2194279T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9801109.1A GB9801109D0 (en) 1998-01-20 1998-01-20 Cyclodextrin compositions

Publications (1)

Publication Number Publication Date
ES2194279T3 true ES2194279T3 (es) 2003-11-16

Family

ID=10825529

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98310562T Expired - Lifetime ES2194279T3 (es) 1998-01-20 1998-12-22 Composiciones de ciclodextrina que contienen un derivado de avermectina o de milbemicina.

Country Status (11)

Country Link
US (1) US20020032161A1 (es)
EP (1) EP0930077B1 (es)
JP (2) JPH11255646A (es)
AT (1) ATE237359T1 (es)
BR (1) BR9900114A (es)
CA (1) CA2259699A1 (es)
DE (1) DE69813496T2 (es)
DK (1) DK0930077T3 (es)
ES (1) ES2194279T3 (es)
GB (1) GB9801109D0 (es)
PT (1) PT930077E (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091192B1 (en) * 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
BRPI0200751B1 (pt) * 2002-02-06 2018-10-23 Univ Minas Gerais complexos de inclusão de benzaldeído semicabazona em ciclodextrinas e seu método de preparação
EP2277551B1 (en) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
WO2005014010A1 (en) * 2003-07-24 2005-02-17 Eli Lilly And Company Pharmaceutical composition comprising gemcitabine and cyclodextrines
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
CA2703008A1 (en) 2007-11-15 2009-05-22 Novartis Ag Anthelmintic paste comprising praziquantel, a macrolide lactone, cyclodextrin and a thickener
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN104208017A (zh) * 2013-05-29 2014-12-17 镇江威特药业有限责任公司 一种伊维菌素溶液及其制备方法
FR3042412A1 (fr) * 2015-10-14 2017-04-21 Biotopic Pharmaceuticals Formulation pharmaceutique stabilisee et prete a l'emploi d'ivermectine dans le traitement des parasitoses humaines et animales
CN110248648B (zh) * 2016-11-16 2023-02-24 艾维塔生物医学公司 细胞膜结合信号因子的应用
KR20200103660A (ko) 2017-11-16 2020-09-02 에이비타 바이오메디컬, 인크. 세포막 결합된 신호전달 인자의 용도
WO2022034226A1 (en) 2020-08-14 2022-02-17 Universidad De Navarra Avermectin and milbemycin compositions for inhalation
US11253533B1 (en) * 2020-11-10 2022-02-22 Mountain Valley Md Inc Water dissolvable macrocyclic lactone cyclodextrin complexes
US11077134B1 (en) * 2020-11-10 2021-08-03 Mountain Valley Md Inc Water dissolvable macrocyclic lactone cyclodextrin complexes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT750907E (pt) * 1995-06-30 2002-08-30 American Cyanamid Co Formulacoes de vacinas estaveis para administracao parenterica metodo para a sua utilizacao e processo para a sua preparacao

Also Published As

Publication number Publication date
PT930077E (pt) 2003-07-31
ATE237359T1 (de) 2003-05-15
GB9801109D0 (en) 1998-03-18
DE69813496D1 (de) 2003-05-22
BR9900114A (pt) 2000-05-02
DE69813496T2 (de) 2003-10-30
EP0930077A1 (en) 1999-07-21
DK0930077T3 (da) 2003-08-04
JPH11255646A (ja) 1999-09-21
CA2259699A1 (en) 1999-07-20
JP2006083186A (ja) 2006-03-30
US20020032161A1 (en) 2002-03-14
EP0930077B1 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
ES2194279T3 (es) Composiciones de ciclodextrina que contienen un derivado de avermectina o de milbemicina.
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
ES2181744T3 (es) Hidratos de paclitaxel cristalinos.
ES2184293T3 (es) Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina.
FI943749A (fi) Taksaanijohdannaisten fosfono-oksimetyylieetterit
DK0388019T3 (da) Avermectin-ketal-derivater, der er egnede som antiparasitiske midler
AR005640A1 (es) Composiciones endoparasiticidas
CY1106076T1 (el) Παραγωγα γλυκοπυρανοσυλοξυβενζυλο βενζολιου και ιατρικες συνθεσεις που πepιεχουν τα ιδια
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
AU2001289438A1 (en) Pharmaceutical semi-solid composition of isotretinoin
DK0979089T3 (da) Fremgangsmåder til anvendelse af makrocykliske lacton-forbindelser som multilægemiddel-resistens-reverterende midler i tumor og andre celler
FR2451192A1 (fr) Agent de prevention de la mauvaise haleine contenant de la cyclodextrine
BR0116052A (pt) imidazoquinolinas substituìdas por éter arìlico
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
PT1300398E (pt) Processos e composicoes para terapias do cancro, utilizando genes que codificam o interferao-beta
BR9915800A (pt) Produto terapêutico para supressão dos ruìdos de ronco
ES2129078T3 (es) Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion.
ATE162796T1 (de) 4-a-substutierte avermectinderivate
BR0208274A (pt) Composições antitumorais contendo derivados de taxano
BR9610527A (pt) Novos derivados de substâncias de ciclodepsipeptìdeo pf1022
EP1834670A3 (en) Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds
DE69805165T2 (de) Isocyanat-vernetzbare, wässrige zusammensetzungen niedrigen gehalts an flüchtigen organischen verbindungen
FR2708609B1 (fr) Dérivés de méthylguanidine, leurs procédés de préparation ainsi que les compositions en contenant.
ES2164660T3 (es) Derivados difluoro de avermectina.
DE69936052D1 (de) N1 modifizierte glycopeptide